Investing.com -- INmune Bio Inc. (NASDAQ: INMB) stock surged 28% after the company announced its Phase I/II trial of INKmune™ in metastatic castration-resistant prostate cancer (mCRPC) met both ...

INmune Bio Inc. (NASDAQ:INMB) saw its stock jump 28% on Monday after announcing that its Phase I/II trial evaluating INKmune™ ...

INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, is pleased to report that its Phase I/II trial (the “CaRe PC” trial) of INKmune™ for men with ...

Shares of INmune Bio climbed after the biotech company said its trial for treatment of a certain prostate cancer met its targets. The stock was up 11%, to $2.83, but is still down 65% over the ...

Kaveri Pohlman has given his Buy rating due to a combination of factors, including the promising initial results from the INKmune program and its potential in a significant market. The program’s ...

“INKmune™ can be given to men with mCRPC in an out-patient setting and so far has an exemplary safety profile,” said RJ Tesi, MD CEO of INmune. “Data from the low dose cohort has shown ...

Boca Raton, Florida, April 29, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (INMB) (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that ...

INKmune™ is tumor agnostic; it can be used to treat many types of NK-resistant tumors including leukemia, lymphoma, myeloma, lung, ovarian, breast, renal and nasopharyngeal cancer.

INKmune™, a therapeutic composition comprising replication incompetent INB16 cells, is modified to prevent proliferation in a patient’s body, but provides certain signals necessary to ...

INKmune™ is a pharmaceutical-grade, replication-incompetent human tumor cell line which conjugates to resting NK cells and delivers multiple, essential priming signals to convert the cancer ...

CAR-NK immunotherapies do not come with this issue. INKmune for the treatment of cancer: high-risk MDS/AML and a large solid tumor INmune Bio is running a Phase I trial in high-risk MDS/AML in the UK.

Once INKmune™ binds to the patient’s circulating, resting NK cells, the NK cells move from their state of “rest” to a state or readiness we call “primed” and are “ready to kill.” ...